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Abstract  The  introduction  of  the  anti-tumor  necrosis  factor  agents  (anti-TNF)  in  clinical
practice has  greatly  advanced  the  treatment  of  inﬂammatory  bowel  disease.  The  use  of  these
medications  results  in  durable  remission  in  a  subset  of  patients,  preventing  surgery  and  hos-
pitalizations.  However,  there  are  some  concerns  about  safety  and  costs  associated  with  their
long-term use.  Therefore,  anti-TNF  withdrawal  has  emerged  as  an  important  consideration  in
clinical practice.  Herein  our  goal  was  to  discuss  the  available  evidence  about  anti-TNF  discon-
tinuation in  IBD  that  could  inform  the  clinician  on  the  expected  rates  of  relapse,  the  potential
predictors  of  relapse,  as  well  the  response  to  re-treatment.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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tratamento  da  doenc¸a  inﬂamatória  intestinal.  A  utilizac¸ão  destes  medicamentos  resulta  numa
remissão duradoura  num  sub-grupo  de  doentes,  evitando  cirurgias  e  hospitalizac¸ão.  No  entanto,
existem algumas  preocupac¸ões  com  a  seguranc¸a e  o  custo  associados  com  a  sua  utilizac¸ão  a  longo
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prática  clínica.  Pretendemos  neste  artigo,  discutir  a  evidência  disponível  sobre  interrupc¸ão  dos
anti-TNF na  doenc¸a  inﬂamatória  intestinal,  proporcionando  ao  clínico  informac¸ão  actualizada
sobre as  taxas  de  recidiva  após  interrupc¸ão  do  fármaco,  potenciais  factores  predictores  de
recidiva, assim  como  a  resposta  ao  re-tratamento.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.  Este  é
um artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.org/licenses/
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p. Introduction
he  introduction  of  anti-TNF  has  changed  the  course  of
nﬂammatory  bowel  disease  (IBD).  These  drugs  have  proven
fﬁcacious  in  healing  the  mucosa,  and  in  reducing  surgi-
al  and  hospitalizations  rates.  Their  introduction  in  the
linic  led  to  major  shifts  in  the  therapeutic  paradigm  that
volved  from  mere  symptomatic  clinical  remission  toward
ustained  and  deep  remission.  In  parallel  with  the  evolu-
ion  of  these  therapeutic  goals,  we  have  also  seen  a shift
n  treatment  strategies  in  IBD.  Central  to  these  strate-
ies  are  the  early  introduction  of  immunosuppression,  the
apid  escalation  to  anti-TNF  therapies  (accelerated  step-up
trategy)  or  the  early  introduction  of  combination  therapy
top-down  strategy),  allied  with  a  tight  and  frequent  con-
rol  of  inﬂammatory  activity,  and  adjustment  of  therapy
ased  on  that  assessment  (treat-to-target  strategy).1,2 As
 result  of  these  strategies,  there  has  been  an  exponential
ncrease  in  the  number  of  patients  that  are  treated  with
nti-TNF  monotherapy,  or  more  frequently  as  combination
herapy.  However,  despite  their  proven  efﬁcacy,  anti-TNF’s
igh  cost  and  safety  issues  are  among  the  main  concerns
laimed  against  their  long-term  use  that  may  motivate  doc-
ors  and  patients  to  discontinue  the  drugs  when  sustained
nd  deep  remission  has  been  reached.  Questions  on  if,  when
nd  in  whom  we  should  discontinue  anti-TNF  are  actively
ebated  by  the  scientiﬁc  community.  Many  studies  have  now
eported  on  the  relapse  rates  following  drug  de-escalation,
n  the  hope  of  identifying  a  subset  of  patients  in  whom  ther-
py  could  be  reduced  to  the  minimal  effective  therapy  that
ould  maintain  remission.  However,  so  far  no  deﬁnitive  evi-
ence  or  strategy  has  been  deﬁned.  Herein,  our  goal  was
o  review  and  summarize  the  available  evidence  about  anti-
NF  discontinuation  in  IBD,  in  a  comprehensive  way  that
ould  provide  information  and  hopefully  guidance  in  clinical
ractice.
. Why is anti-TNF withdrawal considered in
linical  practice?
t  may  seem  counterintuitive  to  stop  a  therapy  once  its
herapeutic  goals  have  been  achieved;  both  clinicians  and
atients  may  be  reluctant,  fearing  relapse  and/or  loss  of
fﬁcacy  in  the  event  of  re-treatment.  However,  therapeutic
e-escalation  is  considered  in  clinical  practice  for  several
easons,  namely:  (1)  safety  concerns  or  side-effects,  (2)
i
a
a
rost/national  regulations,  and  (3)  special  situations  such  as
regnancy,  travel  or  patient  preference.
.1.  Safety
verall,  if  used  with  the  due  precautions,  anti-TNF  agents
ave  a  good  short  and  medium-term  safety  proﬁle.  However,
e  must  also  recognize  that  the  follow-up  time  for  anti-TNF
nd  combination  therapy  is  still  very  limited.  An  example
f  this  can  be  drawn  from  thiopurine  use  in  IBD.  Although
hese  drugs  have  been  used  in  IBD  for  more  than  30  years,3
nly  recently  has  it  been  deﬁnitely  conﬁrmed  their  associa-
ion  with  the  development  of  lymphoproliferative  disorders4
nd  skin  cancer.5 The  increased  risk  of  infections  and/or
alignancies  is  the  most  important  concern  associated  with
ong-term  anti-TNF  therapy  in  IBD,6 especially  when  used
n  combination  therapy.  Anti-TNF  therapies  may  increase
he  risk  of  infections,6 especially  fungal  and  bacterial,7 and
arginally  increase  the  risk  of  melanoma.8 Patients  on  com-
ination  therapy  may  have  an  increased  risk  of  developing
epatosplenic  T-cell  lymphoma,  non-Hodgkin’s  lymphoma,9
nd  infections.6 Certain  populations,  such  as  the  elderly  or
ale  pediatric  patients,10--12 may  be  at  higher  risk  for  spe-
iﬁc  complications.  Furthermore,  side  effects  may  require
rug  discontinuation.
.2.  Cost/national  regulations
n  parallel  with  reduced  surgery  and  hospitalization  rates
n  the  biological  era,13 the  recently  published  COIN  study,14
emonstrated  that  direct  healthcare  costs  in  IBD  are  now
ed  by  medications.  The  goal  of  this  study,  performed
n  the  Netherlands,  was  to  provide  an  updated  overview
f  general  costs  in  IBD  the  current  era  of  expanding
se  of  biologics.  This  study  showed  that  anti-TNF  use
ccounted  for  64%  and  31%  of  the  direct  costs  in  CD  and
C  respectively.14 Conversely,  surgery,  hospitalization,  and
ick  leave  accounted  for  only  19%,  <1%  and  16%  of  the
ealthcare  costs  in  CD,  and  23%,  1%,  and  39%  of  costs
n  UC  patients  respectively.14 Whilst  these  calculations  do
ot  argue  against  the  cost-effectiveness  of  these  thera-
ies  (rather  it  is  the  other  way  around),  these  costs  are
ndeed  substantial.  In  fact,  a  number  of  national  societies
nd  expert  panels  have  recommended  stopping  anti-TNF
fter  one  or  two  year(s)  of  therapy,  provided  that  clinical
emission  has  been  achieved.15--17
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2.3.  Special  situations  (pregnancy,  traveling,
patient preference,  insurance  policies)
An  increasing  number  of  female  IBD  patients  conceive  whilst
under  treatment  with  anti-TNF.  Inﬂiximab  (IFX)  and  adali-
mumab  (ADA)  cross  the  placenta  and  serum  drug  levels  in
the  baby  may  exceed  those  of  the  mother.18,19 Therefore
discontinuation  by  the  end  of  the  second  trimester  is  gener-
ally  recommended  in  pregnant  patients  in  remission.20 Other
special  situation  refers  to  patients  traveling  for  long  periods
in  areas  of  the  world  where  access  to  medications  or  medi-
cal  facilities  is  limited,  or  where  serious  infections  such  as
tuberculosis  are  endemic.  The  decision  to  continue  anti-TNF
in  such  special  situations  needs  to  be  carefully  balanced
against  the  risk  of  relapse,  taking  into  account  patient’s
expectations.
3. What are the relapse rates after stopping?
Clinicians  and  patients  are  often  faced  with  the  question  on
whether  it  is  possible  to  stop  anti-TNF  therapy  given  that
disease  remission  has  been  conquered.  However,  despite
all  the  studies  that  have  now  addressed  this  issue  in  IBD,
no  conclusive  strategy  has  yet  emerged.21 This  may  be
due  to  large  heterogeneity  across  different  studies  pre-
cluding  ﬁrm  conclusions  on  the  ideal  clinical  scenario  when
the  drug  could  be  stopped.  Furthermore,  and  most  impor-
tantly,  it  is  difﬁcult  to  draw  ﬁrm  conclusions  about  the
effect  of  anti-TNF  withdrawal  due  to  the  lack  of  control
data.
3.1.  Anti-TNF  discontinuation  in  Crohn’s  disease
Many  studies  have  now  looked  into  anti-TNF  withdrawal
in  Crohn’s  disease  (see  Table  1  for  a  summary  of  most
relevant  studies).22--33 The  STORI  trial  (Inﬂiximab  diSconTin-
uation  in  Crohn’s  disease  patients  in  stable  Remission  on
combined  therapy  with  Immunosuppressors)  was  the  piv-
otal  study  boosting  clinical  research  in  this  topic,  being
thereafter  followed  by  many  studies.  This  was  a  multicen-
ter  study  led  by  the  GETAID,  and  it  was  the  ﬁrst  prospective
study  speciﬁcally  designed  to  assess  the  risk  of  relapse,
and  to  identify  predictors  of  relapse  following  anti-TNF
maintenance  therapy  withdrawal.34 Patients  entering  the
trial  had  to  be  in  steroid-free  remission  for  a  minimum
of  6  months,  while  on  at  least  1  year  of  scheduled  IFX
combined  with  a  stable  dose  of  immunomodulators  (aza-
thioprine,  6-mercaptopurine,  or  MTX).  Among  the  115  CD
patients  with  luminal  disease  that  were  enrolled  (perianal
CD  was  excluded),  there  was  a  43.9%  (±5.0%)  rate  of  relapse
over  1  year  and  a  52.2%  (±5.2%)  rate  of  relapse  over  2
years  after  stopping  IFX.  Relapse  occurred  after  a  median
of  16.4  months.  Following  STORI,  many  other  retrospec-
tive  and  prospective  cohorts  followed.  Importantly,  it  is
worth  mentioning,  that  for  most  of  these  studies,  patients
had  the  anti-TNF  discontinued  while  they  were  in  clini-
cal  remission  (with  variable  deﬁnitions  of  clinical  remission
and  variable  duration  of  remission  before  drug  withdrawal).
Interestingly,  the  relapse  rates  among  those  studies  are
fairly  homogenous,  ranging  from  21  to  56%  at  12  months
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nd  from  47  to  64%  at  24  months  respectively24,29,31,34--41 (see
able  1).  An  exception  is  the  study  by  Papamichael  et  al42
hat  reported  lower  relapse  rates  after  drug  discontinua-
ion;  the  cumulative  probability  of  maintaining  sustained
linical  remission  after  the  ﬁrst,  second,  third,  fourth,  and
fth  year  was  96%,  93%,  88%,  79.9%,  and  72.8%,  respec-
ively.  However,  by  the  end  of  follow-up  (median  10  years),
2%  of  patients  had  relapsed.  Studies  with  long  follow-
p  periods  have  reported  high  relapse  rates  ranging  from
7%42 to  65%36 at  5  years,  and  88%  at  10  years.37 The
ong-term  (median  6.9  years)  follow-up  of  the  STORI  trial,
ecently  presented,  showed  that  25%  of  patients  who  discon-
inued  anti-TNF  in  the  original  trial  eventually  developed
owel  damage  (need  for  surgical  resection,  new  perianal
stula).43
The  results  from  the  STORI  trial  suggested  that  patients
ith  deep  remission  (clinical  and  endoscopic)  had  a  very
ow  chance  for  relapse.34 These  results  were  felt  to  be
ncouraging,  as  they  suggested  that  a  subset  of  patients
ho  had  reached  deep  remission  could  be  good  candidates
or  stopping  therapy.  Therefore,  it  was  anticipated  that
topping  anti-TNF  in  patients  presenting  full  endoscopic
nd  biologic  remission,  could  lead  to  even  higher  remis-
ion  rates.  However,  recent  studies  that  recruited  patients
n  deep  remission  (clinical  and  endoscopic  remission)  have
hown  somehow  similar  relapse  rates  between  22--74%  at
2  months,44,45 47--49%  at  24  months,44,46 and  50%  at  36
onths,27 very  similar  to  those  when  anti-TNF  was  dis-
ontinued  while  in  clinical  remission.  For  example,  in  a
ecently  published  cohort,  patients  who  discontinued  the
nti-TNF  after  endoscopic  remission  (absence  of  ulcerations)
as  attained,  were  prospectively  followed.46 The  cumu-
ative  probability  of  relapse  at  2  years  was  49%.46 The
uthors  compared  the  relapse  rates  between  the  subset
f  patients  that  besides  endoscopic  remission  also  pre-
ented  biological  remission  (FC  <  150  mg/kg  and  CRP  levels
5  mg/L)  to  those  who  only  presented  clinical  and  endo-
copic  remission  only.  The  relapse  rates  at  2  years  were
0%  and  52%  respectively  (non-signiﬁcant).  Although  these
ata  require  further  conﬁrmation,  in  appropriately  powered
ohorts,  they  are  somehow  disappointing,  raising  the  pos-
ibility  that  even  after  deep  remission  has  been  achieved,
he  disease  will  eventually  resume  its  trajectory  and  the
nﬂammatory  cascade  will  relapse,  after  the  drug  has  been
iscontinued.
.2.  Anti-TNF  discontinuation  in  ulcerative  colitis
ike  in  CD,  most  of  the  studies  that  have  been  made  study-
ng  anti-TNF  discontinuation  in  UC  are  very  heterogeneous
see  Table  2).  Nevertheless,  the  reported  relapse  rates  are
omehow  similar,  perhaps  slightly  lower  than  CD.  Stud-
es  in  adult  populations  have  reported  relapse  rates  that
ange  between  14--42%  at  12  months,  and  25--47%  at  24
onths24,37,38,41,47--50 (see  Table  2).  Studies  where  anti-TNF
as  discontinued  after  mucosal  healing  had  been  attained,
eport  similar  relapse  rates  at  12  and  24  months  of  17--25%
nd  25--35%  respectively47,50.  The  study  with  longest  follow-
p  by  Steenholdt  et  al37 reported  relapse  rates  of  60%  at  4.5
ears.37
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Table  1  Summary  of  most  relevant  studies  speciﬁcally  reporting  on  the  relapse  rates  after  discontinuation  of  anti-TNF  therapy
in adult  populations  with  Crohn’s  disease,  following  a  variable  period  of  therapy  (Note:  only  studies  with  >30  patients  were
included).
Author,  year
(study  type)
No.  of
patients
Deﬁnition  of
remission
%  on
concomitant
IM
Relapse  rate
at  12  months
Relapse  rate
24 months
Outcome  at  last
follow-up
Molnar,  2008
(Retrospective)
50  (treated
with  IND
therapy  only)
Clinical  remission  86%  56%  --  --
Waugh, 2010
(Retrospective)
48  Steroid-free  clinical
remission
67%  -- -- 65%  relapsed  (median
follow-up  of  4.1  Y)
Louis, 2012
(Prospective)
115  Steroid-free  clinical
remission
100%  43.9  ±  5%  52.2  ±  2%  --
Molnar, 2013
(prospective)
121  Clinical  remission  85%  45%  --
Papamichael,  2014
(Retrospective)
100  (65%
treated
episodically)
Clinical  remission  84%  4%  7%  48%  relapsed  (median
follow-up  9.7  Y)
Chauvin, 2014
(Prospective)
92  (54  treated
w/IND  only
and  38
w/MAINT
therapy)
Clinical  remission  100%  IND:  22%
MAINT:  44%
IND:  40%
MAINT:  64%
IND:  74%  (median
follow-up:  4.6  Y)
MAINT:  68%  (median
follow-up:  3.2  Y)
Monterubbianesi,
2015
(Retrospective)
58 Clinical  remission  66%  31%  52%  --
Armuzzi, 2010
(Retrospective)
43  Clinical  remission  NS  --  --  49%  relapsed  (median
follow-up  1.1  Y)
Steenholdt,  2012  53  Clinical  remission  87%  39%  50%  (23
months)
68%  (median
follow-up  1.5  Y)
Dai, 2014
(Prospective)
109  Clinical  remission  41%  21%  --  --
Kennedy, 2015
(Retrospective)
146  Clinical  remission  65%  36%  56%  51%  (median
follow-up  of  2  Y)
Brooks, 2014
(Prospective)
86 Clinical  and/or
endoscopic
remission
80%  36%  --  --
Echarri, 2013
(Retrospective)
32  Steroid-free  clinical
remission,
endoscopic  and
radiological
remission
93%  22%  47%  --
Rismo, 2014
(Prospective)
37  Endoscopic
remission
84%  74%  --  --
Bortlik, 2015
(Prospective)
61  Clinical  and
endoscopic
remission
77%  41%  49%  52.6%  (median
follow-up  2.5  Y)
4
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sY, years; IND, induction; MAINT, maintenance; NS, non-speciﬁed.
. Can we predict relapse after anti-TNF
iscontinuation?
ince  anti-TNF  discontinuation  is  associated  with  high
elapse  rates,  it  is  crucial  to  be  able  to  identify  risk  fac-
ors  for  recurrence  (Table  3)  that  could  inform  on  the
isk/beneﬁt  of  withdrawing.  However,  it  is  important  to
ecognize  that  most  studies  on  anti-TNF  discontinuation
ere  not  adequately  powered  for  determining  risk  factors
r
s
t
(or  recurrence,  and  therefore  clinicians  should  be  cautious
n  relying  exclusively  in  these  factors  for  making  their
ecision.  Stopping  anti-TNF  (or  any  other  therapy)  should
nstead  be  a  personalized  and  individualized  decision,  that
hould  take  into  account  the  presence  of  risk  factors  for
elapse,  patient  phenotype,  patient  preference,  patient
peciﬁc  risk  factors  for  side-effects,  weighing  them  against
he  consequences  of  relapse  in  the  individual  patient21
Fig.  1).
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Table  2  Summary  of  most  relevant  studies  speciﬁcally  reporting  on  the  relapse  rates  after  discontinuation  of  anti-TNF  therapy
in adult  populations  with  ulcerative  colitis/inﬂammatory  bowel  disease  undetermined,  following  a  variable  period  of  therapy.
Author,  year
(Study  type)
No.  of
patients
Deﬁnition  of
remission
%  on
concomitant  IM
Relapse  rate  at
12 months
Relapse  rate
24  months
Relapse  rate  at
last  follow-up
Armuzzi,  2010
(Retrospective)
22  Clinical
remission
NS  41%  (median
follow-up  of
1.3  Y)
Farkas, 2013
(Retrospective)
51  Clinical
remission
73%  --  --  35%  (1  Y
follow-up)
Dai, 2014
(Prospective)
107  Clinical
remission
20%  14%  --  --
Steenholdt, 2012
(Retrospective)
28  Clinical
remission
85%  25%  --  36%  (median
follow-up  of
2.4  Y)
Kennedy, 2015
(Retrospective)
20  Clinical
remission
75%  42%  47%  45%  (median
follow-up  1.9
Y)
Molander, 2014
(Prospective)
35  Clinical,
endoscopic
remission
and  FC  <  100
86%  35%  --  --
Munoz-Villafranca,
2015
(Prospective)
12 Mucosal
healing
NS  25%  25%  --
Y, years; FC, fecal calprotectin; NS, non-speciﬁed.
TAKE-  HOME  ME SSAGES  
Following anti-TNF  discontinuation  in patients in  remi ssion, approximately  50% of patients 
will relapse  over  two  years. Relap se ra tes increase  wi th time.  
A  robust  set   of  predictors  that   can  pr ovide  guidance  regardi ng  patients  in   whom de-
esc alation is li kel y to be  succe ssful  is  still  lac king.  None the less, those who presen t eviden ce 
of  subclinical   disease  activity,  poor  prognostic  feature s,  and   who  had  a prior   relapsing 
cours e are more li kel y to  relap se after  th e dru g is  di sco ntinu ed. 
A close follow  up of  biomarkers   after  discont inuation may allo w to pr edict relapse, offering 
the  opport unity to interven e befor e clinical  symptoms  oc cur. 
Respon se to re-tre atment  is gener ally  goo d an d safe,  however long-term  da ta is mis sing. 
Discontinuation   of  anti-T NF  should be   a  careful ly weighted   decision,   because  the 
conse quences  of   relaps e  can  be  sev ere  an d re sul t in   bowel   damage in cludin g surgery . 
Therefor e, th e ri sks of co ntinuing the dr ug should  be balanced with  patient  pr eferen ce an d 
willingness to accept the risks associated with therapy, risk factors for relapse and the 
conse quences  of  relap se.   
es  onFigure  1  Take-home  messagMost  studies  reporting  on  predictive  factors  for  relapse
were  made  on  Crohn’s  disease,  and  less  evidence  is  avail-
able  in  UC.  Generally  speaking,  risk  factors  for  disease
recurrence  can  be  grouped  into  four  categories:  (1)  factors
i
t
(
i anti-TNF  withdrawal  in  IBD.ndicating  (sub-clinical)  active  disease,  (2)  prognostic  fac-
ors  for  poor  disease  course,  (3)  prior  disease  course,  and
4)  other  mixed  factors  (Table  3).21 Since  many  studies  have
ncluded  patients  that  were  discontinued  while  on  clinical
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Table  3  Factors  predictive  of  relapse  in  IBD  (adapted  from
Torres et  al21).  Note:  only  factors  identiﬁed  through  multi-
variable  analysis  across  different  studies  are  presented  in
this table.
Factors  predictive  of  relapse
Reﬂective  of  disease  activity  at  de-escalation  or  during
follow-up
• Elevated  inﬂammatory  markers  (elevated  leukocyte
count,34,41 elevated  CRP,24,31,34 escalation,51,52 elevated
FC25,34,41
•  Laboratorial  markers  suggestive  of  ongoing  inﬂammation
(low hemoglobin)34
•  Absence  of  mucosal  healing24,34
Factors  reﬂective  of  disease  poor  prognostic  features
• Smoking29,31
•  Perianal  disease29
•  Disease  location  (ileocolonic  disease35;  colonic  versus
ileal or  ileocolonic  disease46)
• Young  age  at  diagnosis41,42
Previous  disease  course
• Prior  disease  course  marked  by  higher  therapeutic
requirements  (higher  steroid  use,34 prior  anti-TNF
course*,31,35,49 need  for  dose-escalation  prior  to
discontinuation,31 prior  immunomodulator  failure29)
Other
• Male  sex  (HR  3.7  [1.9--7.4])34
34
r
b
t
f
e
M
f
t
t
c
t
e
p
p
c
m
r
p
t
t
d
m
f
d
r
t
r
d
t
r
v
s
t
l
p
s
9
d
o
w
t
i
>
m
h
u
a
l
c
a
t
i
i
e
r
t
w
o
i
m
p
w
m
m
a
n
ﬁ
s
r
s
t
5
A
i
s
t
i
a
A
f
e
r•  Elevated/detectable  IFX  trough  levels
* Identiﬁed as risk factor of relapse for UC.
emission,  it  comes  as  no  surprise  that  evidence  of  active
ut  sub-clinical  disease  (reﬂected  as  elevated  inﬂamma-
ory  markers  [elevated  C-reactive  protein  --  CRP,  elevated
ecal  calprotectin  --  FC,  high  leukocyte  count,  etc.],  pres-
nce  of  ulcers  on  endoscopy  or  bowel  wall  thickening  on
RI),  is  consistently  identiﬁed  across  studies  as  predictive
or  relapse.25,34,41,51,52 Therefore,  it  is  legitimate  to  state
hat  clinical  remission  per  se  is  not  enough  of  an  argument
o  stop  a  drug  in  IBD.  Physicians  that  are  considering  on  dis-
ontinuing  anti-TNF  should  always  make  a  full  work-up  on
heir  patients,  including  an  endoscopic  and/or  radiological
xamination  before  making  that  decision.  Those  patients
resenting  risk  factors  that  have  been  associated  with  a
oor  disease  course, such  as  young  age  at  diagnosis,  compli-
ated  phenotype,  and  disease  located  in  the  terminal  ileum,
ore  extensive  disease,  smoking,  etc.,  will  be  more  likely  to
elapse  when  the  drug  is  discontinued.29,31,35,42,46 Likewise,
rior  disease  course  may  be  informative  on  relapse.  Patients
hat  had  in  the  past  a  disease  that  was  more  difﬁcult  to  con-
rol,  or  that  had  higher  therapeutic  requirements,  need  for
ose-escalation  to  achieve  and/or  maintain  remission,  etc.
ay  reﬂect  a  group  with  more  severe  disease,  and  there-
ore  may  be  at  higher  risk  for  relapsing.31,35,49 The  type  and
uration  of  therapy  and  of  disease  may  impact  recurrence
ates,  as  shorter  anti-TNF  duration  and  longer  disease  dura-
ion  before  anti-TNF  have  been  identiﬁed  as  predictors  for
elapse  in  some  studies,  whereas  a  shorter  interval  between
isease  diagnosis  and  starting  anti-TNF,  and  maintaining  the
reatment  with  an  immunomodulator  were  associated  with
g
5
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emission.42,53 Other  factors  have  also  been  identiﬁed.  A
ery  interesting  ﬁnding,  that  has  now  been  replicated  in
ome  studies  is  that  those  patients  who  have  lower  or  unde-
ectable  trough  levels  before  drug  discontinuation  have  a
ower  chance  of  relapse.34,42,54 In  a  retrospective  cohort,
atients  with  IBD  who  discontinued  anti-TNF  while  in  remis-
ion  (endoscopic  or  radiological  remission  documented  in
5%  of  patients)  had  their  trough  levels  measured  before
iscontinuation.  The  odds  for  clinical  relapse  by  12  months
f  follow-up  was  30  times  higher  (95%  CI:  5.8--153)  for  those
ho  presented  detectable  trough  levels  as  compared  to
hose  who  did  not.54 This  ﬁnding  had  also  been  observed
n  the  STORI  trial,  where  presenting  inﬂiximab  trough  level
2  mg/L  (HR  2.5  [1.1--5.4)]  was  predictive  for  relapse.34 This
ay  seem  counterintuitive,  as  absence  or  low  trough  levels
ave  been  associated  with  worse  outcomes,55 boosting  the
se  of  therapeutic  drug  monitoring  in  the  clinic  for  ther-
py  optimization.  However,  for  the  subset  of  patients  in
ong-lasting  remission,  low/absent  trough  levels  may  indi-
ate  that  remission  is  no  longer  driven  by  the  anti-TNF,
nd  therefore  that  these  patients  no  longer  need  the  drug
o  maintain  the  remission  state.  On  the  same  topic,  it
s  very  interesting  to  note  that  for  patients  stopping  the
mmunomodulator  and  maintaining  the  anti-TNF,  the  pres-
nce  of  good  anti-TNF  trough  levels  is  protective  from
elapse.56 Therefore,  therapeutic  drug  monitoring  may  in
he  future  be  a  powerful  tool  to  select  patients  for  anti-TNF
ithdrawal.
One  very  important  message  that  arose  from  a  sub-study
f  the  STORI  trial  and  was  later  conﬁrmed  in  another  cohort
s  that  clinical  relapse  is  preceded  by  elevation  of  inﬂam-
atory  markers.51,52 In  STORI’s51 prospective  follow-up,  113
atients  had  bimonthly  measurements  of  CRP  and  FC;  those
ho  later  relapsed,  presented  a  marked  rise  in  these  inﬂam-
atory  markers  occurring  4  months  before  relapse.  The
edian  value  for  FC  and  CRP  before  relapse  was  534  g/g
nd  8  mg/L  for  relapsers  and  66.9  g/g  and  3.7  mg/L  for
on-relapsers,  respectively.51 These  ﬁndings  have  been  con-
rmed  in  another  cohort52, and  indicate  that  in  patients
topping  anti-TNF,  a  close  follow-up  with  regular  laborato-
ial  assessment,  may  allow  to  diagnose  relapse  even  before
ymptoms  occur,  offering  the  possibility  for  early  interven-
ion.
. Can we re-treat after we stop?
 reassuring  message  arising  from  some  studies  is  that
f  relapse  occurs,  re-treatment  may  be  successfully  and
afely  re-instituted.  A  signiﬁcant  proportion  of  the  patients
hat  relapsed  across  studies  were  re-treated.  Most  stud-
es  only  provided  the  rates  of  clinical  remission/response
fter  re-treatment  with  no  further  details.30,31,36,41,44,57,58
lso,  most  studies  have  only  reported  short-term  results,
requently  for  the  induction  therapy  phase.  Apart  from  some
xceptions,31,36 the  short-term  remission/response  rates  to
e-treatment  (often  using  the  same  biologic  agent)  were
enerally  very  good,  ranging  from  78%  to  100%  in  CD  and
4--100%  in  UC.38,41,47,49 Studies  reporting  longer  follow-up  of
t  least  one  year  reported  clinical  remission  rates  between
0  and  92%  at  one  year35,50,53 for  CD.
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6. Unanswered questions and perspectives
There  are  many  unanswered  questions  that  are  worth  men-
tioning.  The  ﬁrst  and  most  important  is  that  so  far  there
is  no  controlled  study  that  can  really  answer  the  question
on  whether  maintaining  the  anti-TNF  is  superior  to  maintain
remission  as  opposed  to  discontinuing  the  drug.  In  second
place,  there  is  a  lack  of  studies  appropriately  powered,
looking  into  the  possibility  of  reducing  the  dose  of  the  anti-
TNF  once  remission  has  been  attained,  although  this  could
be  an  interesting  approach  for  reducing  costs  and  perhaps
adverse  effects.59 In  rheumatoid  arthritis  for  example,  a
meta-analysis  on  de-escalation  of  anti-TNF  in  randomized
and  controlled  clinical  trials  in  patients  with  rheumatoid
arthritis  (RA),  showed  that  while  reducing  the  drug  dose
(etarnecept  data  only)  was  not  associated  with  worse  out-
comes,  stopping  the  drug  (etarnecept  or  adalimumab  data)
led  to  higher  rates  of  clinical  activity  and  worse  radiological
and  functional  outcomes.60 In  IBD,  three  small  studies  have
explored  this  possibility  with  apparently  good  results.22,25,61
Third,  stopping  the  anti-TNF  when  the  drug  has  been  used  as
monotherapy  has  also  not  been  adequately  studied  in  IBD,
which  reﬂects  the  clinical  practice  where  these  agents  are
often  used  in  combination  with  an  immunomodulator  agent.
Fourth,  it  is  also  very  interesting  to  acknowledge  that  are
no  studies  speciﬁcally  studying  anti-TNF  discontinuation  in
early  disease.  Evidence  from  rheumatology  suggests  that
studies  focusing  on  drug  withdrawal  after  early  drug  treat-
ment  with  anti-TNF  may  be  more  fruitful.62 Finally,  the  topic
of  personalizing  discontinuation,  taking  into  account  the
speciﬁc  patient  risk  for  complications  development  needs
to  be  further  explored.10
Clearly,  the  topic  of  drug  de-escalation  is  a  very  impor-
tant  one  in  IBD  and  warrants  further  research.  A  large
European  Union  funded  trial  (Biocycle  project)  will  soon
start  and  likely  solve  many  of  the  answered  questions.63
This  large  multicenter  project  will  for  the  ﬁrst  time  study
different  discontinuation  strategies  in  a  controlled  fash-
ion.  Patients  with  CD  in  sustained  steroid-free  remission
on  combination  therapy  will  be  randomized  to  continuing
therapy,  discontinuing  the  anti-TNF  or  the  immunomodula-
tor.  The  results  of  this  trial  will  be  then  used  to  inform  the
concept  of  treatment  cycles  in  IBD,  characterized  by  periods
where  both  anti-TNF  and  immunomodulators  are  adminis-
tered  alternating  with  periods  where  either  of  the  drug  is
withdrawn  after  remission  has  been  reached.  Hopefully  this
large  trial  will  inform  us  on  how  to  make  the  best  use  of  the
current  therapeutic  strategies  we  currently  have,  shedding
some  light  into  this  important  question  in  clinical  practice.
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